FHLC - Fidelity MSCI Health Care Index ETF
| Assets | $2.60B |
| NAV | $60.93 |
| Expense Ratio | 0.08% |
| PE Ratio | 25.95 |
| Beta (5Y) | 0.80 |
| Dividend (ttm) | $0.78 |
| Dividend Yield | 1.29% |
| Ex-Dividend Date | Mar 19, 2021 |
| 1-Year Return | - |
| Trading Day | April 16 |
| Last Price | $61.31 |
| Previous Close | $60.90 |
| Change ($) | 0.41 |
| Change (%) | 0.67% |
| Day's Open | 61.08 |
| Day's Range | 60.94 - 61.35 |
| Day's Volume | 98,764 |
| 52-Week Range | 46.38 - 61.35 |
Fund Description
The investment seeks to provide investment returns that correspond, before fees and expenses, generally to the performance of the MSCI USA IMI Health Care 25/50 Index. The fund invests at least 80% of assets in securities included in the fund's underlying index. The fund's underlying index is the MSCI USA IMI Health Care 25/50 Index, which represents the performance of the health care sector in the U.S. equity market. It may or may not hold all of the securities in the MSCI USA IMI Health Care 25/50 Index. The fund is non-diversified.
| Asset Class Equity | Sector Healthcare |
| Region North America | Inception Date Oct 21, 2013 |
| Exchange NYSEARCA | Ticker Symbol FHLC |
| Index Tracked MSCI USA IMI Health Care Index | |
Top 10 Holdings
40.75% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 7.88% |
| UnitedHealth | UNH | 6.36% |
| Abbott Laboratories | ABT | 3.90% |
| Pfizer | PFE | 3.67% |
| Merck | MRK | 3.51% |
| AbbVie | ABBV | 3.44% |
| Thermo Fisher Scientific | TMO | 3.43% |
| Medtronic | MDT | 2.98% |
| Eli Lilly | LLY | 2.89% |
| Danaher | DHR | 2.70% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 19, 2021 | $0.201 | Mar 24, 2021 |
| Dec 18, 2020 | $0.234 | Dec 23, 2020 |
| Sep 18, 2020 | $0.176 | Sep 23, 2020 |
| Jun 19, 2020 | $0.173 | Jun 24, 2020 |
| Mar 20, 2020 | $0.254 | Mar 25, 2020 |
| Dec 20, 2019 | $0.093 | Dec 26, 2019 |
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
Philip Morris’s stock is dropping today along with the broad market as the company that makes Marlboro cigarettes told Irish retailers it made a “mistake” by showing an advertisement in the trade press ...
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
The Vanguard Health Care ETF (VHT) and other healthcare ETFs have been trading higher amid news that U.S. health officials may finally have a potential discovery in the vaping illness outbreak that’s ki...
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
The electronic cigarette market is a burgeoning global industry that includes vaping, and is forecast to expand from less than $10 billion now to over $50 billion by 2025, causing many to consider inves...
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.
Health care's sharp drop comes as investors worry that left-leaning policy ideas like universal health coverage are gaining support.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.